|
WO2017083925A1
|
|
Compounds and methods for treating metabolic disorders
|
|
KR20170099939A
|
|
Sequencing control
|
|
WO2015031958A1
|
|
Regulatory molecules
|
|
WO2014000058A1
|
|
Method of treating glucose metabolism disorders
|
|
CN103619877A
|
|
Modified variable domain molecules and methods for producing and using them b
|
|
US2014106354A1
|
|
Method of Diagnosing Cancer
|
|
WO2012000036A1
|
|
Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1
|
|
EP2470565A1
|
|
Modified variable domain molecules and methods for producing and using same
|
|
WO2010132958A1
|
|
Methods for predicting responsiveness to treatment
|
|
US2011003013A1
|
|
Method of increasing metabolism
|
|
CA2694863A1
|
|
Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
|
|
WO2008113134A1
|
|
Method of transplantation of a kidney
|
|
WO2008061299A1
|
|
Method of treating diabetes
|
|
WO2008043142A1
|
|
Method of treating hearing loss
|
|
WO2008028257A1
|
|
Diagnostics and therapeutics of neurological disease
|
|
AU2006235216A1
|
|
Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
|
|
CA2604423A1
|
|
Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor
|
|
WO2006108225A1
|
|
Method of screening for compounds that modulate cell proliferation
|
|
WO2006050573A1
|
|
Method of diagnosing cancer and reagents therefor
|
|
WO2006015453A1
|
|
Modified dynorphin expression in animals and identification of compounds for treatment of obesity and diabetes
|
